Angiotech Pharma (ANPI) Announces FDA Okay For New TAXUS Stent
More News related to ANPI
- Angiotech Pharmaceuticals, Inc. announces financial results for the third quarter ended September 30, 2009
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Angiotech Pharmaceuticals announces commercial launch of the Tan Endoglide(TM) Endothelium Insertion System in the United States at the American Academy of Ophthalmology annual meeting
- Angiotech Pharmaceuticals (ANPI) Receives FDA Letter Regarding 510k Submission of Bio-Seal
- Angiotech Pharmaceuticals provides update on Bio-Seal(TM) 510(K) submission
More News related to BSX
- Boston Scientific (BSX) Receives 510(k) Clearance and CE Mark on WallFlex
- Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent
- UBS Upgrades Boston Scientific (BSX) to Buy
- Trading Review for Viking Systems Inc. Issued by Beacon Equity
- Notable Analyst Rating Changes 11/17: XOM, PALM, ALKS, ITW, SINA Upgraded; SPWRA, PARD, PSUN, JOYG Downgraded
More News related to FDA
- Cornerstone Therapeutics (CRTX) Receives Warning Letter From FDA
- Pfizer (PFE) Gets Okay for Bipolar Treatment Geodon from U.S. FDA
- Intuitive Surgical (ISRG) Receives Japanese Approval for da Vinci
- Dendreon Corp. (DNDN) Receives U.S. FDA Complete Response for PROVENGE CRPC Treatment
- Boston Scientific (BSX) Receives 510(k) Clearance and CE Mark on WallFlex
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received approval from the FDA to market its TAXUS Liberte Atom Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent specifically designed for treating small coronary vessels.
It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS Express Atom Stent as the only drug-eluting stents approved for small vessel use in the U.S. The Company plans to begin a full U.S. launch of TAXUS Liberte Atom next month.
Related Categories
FDAStocks Mentioned
+0.01
-0.12Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
